The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2010
Impact of HPV vaccination on young women's quality of life - a five year follow-up study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Woodhall Sarah, Eriksson Tiina, Nykänen Anna-Mari, Huhtala Heini, Rissanen Pekka, Apter Dan, Paavonen Jorma, Lehtinen Matti
Аннотация
OBJECTIVES: Human papillomavirus (HPV) vaccines protect against infections/conditions which potentially adversely affect quality of life (QoL). We investigated the impact of HPV infection on QoL five years post vaccination in 22-23 year-old women and a group of controls.
METHODS: Participants were 22-23 year-old women who had either previously been enrolled in the FUTURE II trial of the quadrivalent HPV vaccine in Finland at age 16-17 (n = 1749), or were unvaccinated females in the birth cohort above those eligible for participation in FUTURE II in Finland (n = 6534). Participants were sent a questionnaire consisting of two generic QoL instruments (RAND36 and EQ VAS).
RESULTS: We received and analysed 4438 valid responses. Unadjusted mean outcomes of the different QoL measures (RAND36 domains and EQ VAS) were similar. Multiple regression analysis showed that reporting current or previous genital warts, or cytological abnormalities, was significantly associated with reduced QoL. There were no significant differences between the HPV-vaccinated group and the placebo or unvaccinated groups.
CONCLUSIONS: Diagnoses of genital warts or of cervical anomalies have a significant impact on QoL. The QoL of women who received the placebo or no vaccine was no lower, five years later, than that of those who received the active HPV vaccine.
METHODS: Participants were 22-23 year-old women who had either previously been enrolled in the FUTURE II trial of the quadrivalent HPV vaccine in Finland at age 16-17 (n = 1749), or were unvaccinated females in the birth cohort above those eligible for participation in FUTURE II in Finland (n = 6534). Participants were sent a questionnaire consisting of two generic QoL instruments (RAND36 and EQ VAS).
RESULTS: We received and analysed 4438 valid responses. Unadjusted mean outcomes of the different QoL measures (RAND36 domains and EQ VAS) were similar. Multiple regression analysis showed that reporting current or previous genital warts, or cytological abnormalities, was significantly associated with reduced QoL. There were no significant differences between the HPV-vaccinated group and the placebo or unvaccinated groups.
CONCLUSIONS: Diagnoses of genital warts or of cervical anomalies have a significant impact on QoL. The QoL of women who received the placebo or no vaccine was no lower, five years later, than that of those who received the active HPV vaccine.